MEDI-528, now recognized as enokizumumab, represents a groundbreaking treatment targeting the IGF1R, a crucial protein implicated in several epidermal diseases . Early clinical findings suggest https://cyruspcqu778568.blogdigy.com/enokizumab-a-deep-dive-into-medi-528-and-its-potential-65776692